

PRIOR AUTHORIZATION REQUEST FORM

SUBCUTANEOUS METHOTREXATE

Otrexup®, Rasuvo®, RediTrex™

For authorization, please answer each question and fax this form PLUS chart notes back to Real Rx at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If y	ou have prior authorization question	ns, please call for assistance 38	5-425-5	094.			
Dis	claimer: Prior authorization request for	ms are subject to change in accord	lance wi	th Fede	ral and State notice requirements.		
Dat	re:	Member Name:		ID#:			
DOD:		Gender:		Dhye	Physician:		
DOB:		Gender:		PHYS	'SICIATI.		
Office Phone:		Office Fax:		Offic	e Contact:		
Hei	ght/Weight:						
preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria. Preferred: □ Rasuvo™ (methotrexate)* Non-preferred: □ Otrexup® (methotrexate), □ RediTrex™ (methotrexate) *does not require prior authorization Dosing/Frequency: □ Otrexup® (methotrexate)							
If the request is for reauthorization, proceed to reauthorization section							
	Question	S	Yes	No	Comments/Notes		
1.	Is this request for an expedited reveloped By checking the "Yes" box to request hours), you are certifying that apple frame (72 hours) may place the meto regain maximum function in serior	est an expedited review (24 ying the standard review time ember's life, health, or ability					
2.	Has the member been diagnosed varthritis or polyarticular juvenile id recalcitrant, disabling psoriasis?	•					
3.	Has the member had a trial and fai	lure with oral methotrexate?			Please provide documentation		
4.	Has the member had a trial and fai intramuscular methotrexate?	lure, with subcutaneous or			Please provide documentation		
5.	Is the member unable to draw up range or self-administer, due to environmental factors?				Please provide documentation		
		REAUTHORIZATION					
1. 2.	Is the request for reauthorization of Has the member's therapy been remonths?	• •					

3. Has the therapy shown to be tolerable and effective with an improvement in condition?			Please provide documentation				
4. Does the member show a continued medical need for the therapy?			Please provide documentation				
What medications and/or treatment modalities have been tried in the past for this condition? Please document							
name of treatment, reason for failure, treatment dates, etc.							
Additional information:							
Dharisis n/s Cisastans							
Physician's Signature:							

** Failure to submit clinical documentation to support this request will result in a dismissal of the request.**

Policy: PHARM-070

Origination Date: 11/12/2018 Reviewed/Revised Date: 07/31/2023 Next Review Date: 07/31/2024 Current Effective Date: 08/01/2023

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.